ABSCIENCES (EPA:AB) Initial public offering of AB Science on NYSE Euronext -Revised terms and conditions

Transparency directive : regulatory news

21/04/2010 08:00

Not for distribution directly or indirectly in the United States, Canada,
Australia or Japan

                                                   Paris, April 21st 2010, 8 am

                         Initial public offering of AB Science on NYSE Euronext

                                                   Revised terms and conditions

*  Indicative price range between 12.30EUR and 13.00EUR per share

*  Size of the Offering: 726,820 existing shares and 1,305,700 newly issued
   shares, or 25.7 MEUR (on the basis of the mid point of the initial public
   offering price range)

*  An extension clause : up to 304,878 supplementary existing shares

*  Over-allotment option : up to 350,609 supplementary existing shares

*  Subscription period is expected to end on April 22nd 2010, for both the
   Public Offering and the Global Placement

*  Final offering price expected on April 23rd 2010, and trading on Euronext
   Paris (Compartment B) is expected on April 26th 2010

AB Science has revised the terms and conditions of its initial public offering
and proposed listing of its shares on Euronext Paris, Compartment B.

The targeted gross proceeds from the issue of new shares during the Public
Offering in France and Global Placement should be approximately 16.5 MEUR
(versus 20.2 MEUR initially planned in the Prospectus approved by the AMF on
April 07th 2010 under the number 10-084).

The Public offering in France and the Global placement will close on April 22nd
2010 at 17:00 (Paris time). The settlement and delivery is planned on April 28th
2010, and trading should start on April 26th 2010.

New terms and conditions of the Offering are as follows:

Number of shares offered in the Public Offering and Global Placement:

Offering : 2,032,520 shares offered, including 1,305,700 new shares to be issued
and 726,820 existing shares to be sold, i.e. an overall amount of 25.7 MEUR.

Indicative price range: 12.30 EUR - 13.00 EUR

Extension clause: The number of shares offered may be increased by a maximum of
304,878 supplementary existing shares to be sold, i.e. 15% of the initial
offering.

Over-allotment option: The number of shares offered may be increased by a
maximum of 350,609 supplementary existing shares to be sold, i.e. 15% of the
initial offering (including the Extension clause).

If the extension clause and over-allotment option are exercised, gross proceeds
from the Offering should amount to 34.0 MEUR (of which 16.5 MEUR from newly
issued shares and 17.5 MEUR for the selling shareholders).

The indicative timetable of the Offering, as extended on April 20th 2010, stands
as follows:

21 April 2010    Nyse Euronext notice relative to the revised terms and
                 conditions of the Offering Release of a financial notice
                 in the newspaper la Tribune
22 April 2010    Close of the OPO and the Global placement (17h Paris time)
23 April 2010    Fixing of the final Price of the Offering by the Board of
                 Directors
                 Nyse Euronext notice relative to the result of the OPO
                 Press release indicating the final price and number of shares
                 of the Offering 26 April 2010 Start of trading on
                 Euronext Paris
28 April 2010    Settlement/delivery
21 May 2010      Deadline for exercising the Over-allotment option
                 End of stabilization period

Revocability of orders issued in the OPO:
Orders issued in the OPO before release of the financial notice in La Tribune on
April 21st 2010 shall be
maintained except where they are expressly revoked before April 22nd 2010 (17:00
hours Paris time). New irrevocable orders may be issued up to and including
April 22nd 2010.

The French securities regulator (l'Autorité des marchés financiers - the AMF)
granted visa n° 10-084 on April 7th 2010 to the Prospectus relating to AB
Science's initial public offering, comprising its Document de base registered on
February 10th under number I.10-006, an update of the Document de base filed
with the AMF on Apri l7th and a Note d'opération (including the summary of the
Prospectus).

Banking syndicate

SOCIETE GENERAL
Lead manager and bookrunner    Joint lead manager: Fortis Bank Nederland

Public information

The legal and financial documents required to be made available to shareholders
may be consulted at the registered office of the Company, 3 avenue George V,
75008 Paris.

Copies of the Prospectus are available free of charge from the Company and from
the Lead Manager and Bookrunner and the Joint-Lead Manager. The Prospectus may
be viewed on the websites of the Company (www.ab-science.com) and the AMF
(www.amf-rance.org).

The attention of investors is drawn to Section 4, "Risk Factors", contained in
the Document de base registered with the AMF, the update of such Document de
base filed with the AMF and to Section 2 "Risk Factors" contained in the Note
d'opération.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase inhibitors (PKIs),
a new class of targeted molecules whose action is to modify signalling pathways
within cells. Through these PKIs, the Company targets diseases with high unmet
medical needs (cancer, inflammatory diseases and central nervous system
diseases), in both human and veterinary medicines. Thanks to its extensive
research and development capabilities, AB Science has its own portfolio of
molecules. masitinib, a lead compound, has already been registered in veterinary
medicine in Europe and is pursuing three on-going phases 3 in human medicine in
pancreatic cancer, GIST and mastocytosis.

                 More information on AB Science's website: www.ab-science.com

Contact
Agnès Villeret - Tel: +33 1 5332 7895 - agnes.villeret@citigate.fr
Matthieu Pirouelle - Tel: +33 1 53 3284 77 - matthieu.pirouelle@citigate.fr

Disclaimer

This press release, together with the material set forth herein, does not
constitute an offer of securities for sale nor the solicitation of an offer to
purchase securities in any jurisdiction. Distribution of such press release in
certain jurisdiction may constitute a breach of applicable laws and
regulation.

In particular:

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any financial instruments in the United States. Securities
mentioned in this document have not been and will not be registered under the
Securities Act of 1933, as amended (the "Securities Act") and may not be offered
or sold in the United States absent registration or an exemption from the
registration requirements of the Securities Act. Any public offer of securities
in the United States shall be made by means of a prospectus that may be obtained
from the issuer containing detailed information regarding the Company, its
management andfinancial statements. The Company does not intend to register this
offering in all or in part or to make a public offer of securities in the United
States.

This press release is not an invitation nor is it intended to be an inducement
to engage in investment activity for the purpose of section 21 of the Financial
Services and Markets Act 2000, as amended ("FSMA"). This document is directed
only at (i) persons outside the United Kingdom; or (ii) persons in the United
Kingdom that are "qualified investors" within the meaning of Article 2(1)(e) of
Directive 2003/71/EC including any relevant implementing measure in each member
state, that are also
(a) persons authorised under FSMA or otherwise having professional experience in
matters relating to investments and qualifying as investment professionals under
article 19 of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005, as amended (the "Financial Promotion Order"); or
(b) institutions or corporations qualifying as high net worth persons under
Article 49(2)(a) to (d) of the Financial Promotion Order; or (c) any other
persons to whom this document for the purposes of Section 21 of FSMA can
otherwise lawfully be made (all such persons together being referred to as
"Relevant Persons"). Any person in the United Kingdom that is not a Relevant
Person should not act or rely on this document.

This document contains forward-looking statements. No guarantee can be given as
to any of the events anticipated by the forward-looking statements, which are
subject to inherent risks, including those described in the Prospectus, changes
in economic conditions, the financial markets or the markets in which AB Science
operates.

Société Générale, acting as stabilizing agent, or any institution acting on
its behalf (the "Stabilizing Agent") may, during a period of 30 daysfollowing
the date on which the offering price is determined, ie, according to the
indicative timetable, from April 23 to May 21, 2010, effect transactions with a
view to maintaining the market price of AB Science shares in a manner consistent
with applicable laws and regulations and, in particular, EU Commission
regulation no 22 73/03 of December 22, 2003. However, there is no assurance that
the Stabilizing Agent will take any stabilizing action and, if begun, such
stabilizing action may be interrupted at any time. Any stabilizing action may
affect the price of AB Science shares and could result in marketpricesfor the
shares higher than those which might otherwise prevail.

ABSCIENCES's latest news

15/05/2024 20:16

ABSCIENCES (EPA:AB) Initial public offering of AB Science on NYSE Euronext -Revised terms and conditions

Transparency directive : regulatory news

ABSCIENCES's latest news

Other stories